A patent portfolio is the set of intellectual property rights—granted patents and applications—a company controls around its technology and products.

How it works

Teams file provisional and utility patents with claims defining what is protected. A portfolio may span core algorithms, hardware, manufacturing methods, or drug compounds. Maintenance fees, international filings, and continuations add cost and scope. Due diligence checks ownership (employee assignments), encumbrances, and freedom-to-operate opinions—whether you infringe others’ patents.

Software investors often weight execution and network effects over patent counts; hardware, medtech, and life sciences may treat portfolios as core assets. Acquirers sometimes buy for IP as much as revenue.

Maintenance and prosecution costs add up across jurisdictions. Boards should review whether each family still maps to shipping product or defensible moats—not every legacy filing deserves renewal fees as the roadmap pivots.

Freedom-to-operate opinions complement portfolio strength—they address whether you infringe others, not whether others infringe you. Both matter in acquirer IP diligence for regulated or hardware-heavy categories.

Why it matters

• Founders: File strategically around real inventions; avoid vanity patents that drain cash without enforceable claims.
• Investors: Quality and claim breadth matter more than quantity. Ask about prior art, litigation risk, and whether IP aligns with the product roadmap.

Investors in biotech often map patents to clinical milestones, not just grant counts.

Common mistake

Equating “patent pending” on a deck slide with strong protection. Pending applications may never issue or may issue with narrow claims.

Related ideas

See IP assignment (PIIA), trade secrets, freedom to operate, and defensibility in diligence.